Prostate, Phase III
A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)
Volunteers
Health Professionals
What is the purpose of this trial?
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy,
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Alessia Donadio, MD
- Andrea Brennan
- Armand Russo, MD
- Clarice Grens
- D. Barry Boyd, MD, MS
- Emily Kopas, APRN, OCN
- Harold Tara Jr, MD
- Jose Morales-Marin
- Joseph Kim, MD
- Julie Kang, MD, PhD
- Karishma Mehra, MBBS
- Kayla Martello
- Kevin Du, MD, PhD, MSCI
- Kristen Hoxie
- Larisa Fleysher
- Laura Sabourin
- Lynn Mastrianni
- Madeline Santiago
- Michael Hurwitz, MD, PhD
- Michelle Laspino
- Neal Fischbach, MD
- Nicholas Moore, MD
- Patrick Oh, MD
- Pawan Karanam, MD
- Robert Matera, MD
- Sanjay Aneja, MD
- Sara Anastasio, RN
- Susan Gueble, MD, PhD
- Vidya Kesavan
- Virginia Syombathy
- William K. Oh, MD
- Yifei Zhang, MD
- Zia Rahman, MD
- Last Updated01/06/2026
- Study HIC#2000040718